Opinion
A new nonhormonal option for menopausal hot flashes: What prescribers should know
In two phase 3 clinical trials, fezolinetant 45 mg reduced the frequency of vasomotor symptoms by about 65%.
Article
Is vaginal estrogen used for GSM associated with a higher risk of CVD or cancer?
No. Vaginal estrogen use (average duration of use, 37.5 months) for genitourinary symptoms of menopause (GSM)...
Article
Managing menopausal vasomotor and genitourinary symptoms after breast cancer
Two cases on selecting safe and useful treatments for survivors of breast cancer experiencing distressing quality-of-life...
Audio
Managing menopausal symptoms in breast cancer survivors
What types of menopausal symptoms are breast cancer survivors faced with, and following breast cancer, what treatments should clinicians...
News
Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy
For which of my patients is this treatment appropriate?
Audio
Your menopausal patient’s breast biopsy reveals atypical hyperplasia
How do you now manage her menopausal symptoms, including bothersome hot flashes?
Audio
How I screen patients at increased risk for breast cancer
Hear Dr. Pinkerton discuss: How often women who are at high-risk for breast cancer should be screened New screening tools: breast tomosynthesis...
News
Can nonhormonal treatments relieve hot flushes in breast Ca survivors?
Yes. A Cochrane Review found clonidine, selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs),...
News
“Bioidentical” hormones: What you (and your patient) need to know
Here’s the skinny on compounded “bioidentical” hormone therapy—popular among women but absolutely data-free